ライフサイエンスコーパス: subcutaneous

1 tant high levels of receptor coverage (e.g., subcutaneous).

2 s generated in the chronic phase of repeated subcutaneous 5A7 administration model showed reduced GPI

3 ts were randomly assigned (1:1:1) to receive subcutaneous 80 mg ixekizumab every 4 weeks (Q4W) or eve

4 observed increased GIP-R mRNA expression in subcutaneous abdominal adipocytes from subjects treated

5 Subcutaneous abdominal adipose tissue (SAAT), intra-abdo

6 erwent MRI to assess volumes of visceral and subcutaneous abdominal adipose tissue and liver signal i

7 ificant associations with lower visceral and subcutaneous abdominal adipose tissue volumes and with l

8 findings was confirmed by examination of the subcutaneous abdominal adipose tissue which showed that

9 Total, visceral, and subcutaneous abdominal fat areas were measured by abdomi

10 e plant-based diet indices with visceral and subcutaneous abdominal fat volumes, LSI, and FLD were as

11 ship between RSL and visceral abdominal fat, subcutaneous abdominal fat, total abdominal fat, high to

12 Subcutaneous adipocytes in KO mice show a size distribut

13 to specifically increase RSPO3 expression in subcutaneous adipocytes.

14 When applied to subcutaneous adipose and dorsolateral prefrontal cortex

15 specially between ADH1A and ADH1C within the subcutaneous adipose and gastrointestinal tissues.

16 Subcutaneous adipose cell size was the strongest individ

17 accumulation and enlargement of visceral and subcutaneous adipose depots indicative of both adipocyte

18 Here, we report that subcutaneous adipose expression of the DNA demethylase T

19 ial function in gluteal (gSAT) and abdominal subcutaneous adipose tissue (aSAT) at baseline and in re

20 sociated with increased FAM13A expression in subcutaneous adipose tissue (SAT) and an insulin resista

21 m with mean anterior and posterior abdominal subcutaneous adipose tissue (SAT) depths of 1.6 and 2.0

22 Proper storage of excessive dietary fat into subcutaneous adipose tissue (SAT) prevents ectopic lipid

23 mRNA or protein levels were higher in liver, subcutaneous adipose tissue (SAT), and visceral adipose

24 16243 (CL)-stimulated thermogenic program in subcutaneous adipose tissue (SAT), but not in visceral f

25 als implicated processes in skeletal muscle, subcutaneous adipose tissue and the kidneys, respectivel

26 s attributed to variability in the amount of subcutaneous adipose tissue as the amount of visceral fa

27 IRS-1, GRB14, FST, PEPD, and PDGFC) in human subcutaneous adipose tissue could be associated with inc

28 keeping with this, progressive reduction of subcutaneous adipose tissue is commonly observed.

29 The wireless optogenetics stimulation in the subcutaneous adipose tissue potently activates Ca(2+) cy

30 Body contouring achieved via subcutaneous adipose tissue reduction has notably advanc

31 Paired visceral and subcutaneous adipose tissue samples were obtained from 1

32 ort a role for adipogenesis-related genes in subcutaneous adipose tissue sex differences in the genet

33 We investigated sex differences in subcutaneous adipose tissue transcriptional regulation u

34 Sex differences in associations with subcutaneous adipose tissue were identified.

35 such as total fat mass at DXA, visceral and subcutaneous adipose tissue, and liver and pancreatic fa

36 ssion quantitative trait loci genes in human subcutaneous adipose tissue, and whether expression of t

37 n women for several traits (body mass index, subcutaneous adipose tissue, low-density lipoproteins an

38 that gives rise to thermogenic adipocytes in subcutaneous adipose tissue.

39 smooth muscle actin compared with placebo in subcutaneous adipose tissue.

40 ucture of the lipid networks in visceral and subcutaneous adipose tissues and suggests an integrative

41 veloped macaque model, we show that a single subcutaneous administration of broadly neutralizing anti

42 In contrast, subcutaneous administration of low-dose 5A7 (0.08-0.16 m

43 Subcutaneous administration of Matrigel in Fsp1-Cre: R26

44 In this work, we demonstrate that the subcutaneous administration of Notch2 antisense oligonuc

45 In a diet-induced obesity mouse model, daily subcutaneous administration of OT-12 exhibited more pote

46 Single-dose subcutaneous administration of selatogrel in patients wi

47 inhibition of platelet aggregation following subcutaneous administration of selatogrel in patients wi

48 tients' or controls' CSF, treated with daily subcutaneous administration of SGE-301 or vehicle (no dr

49 olled, multicentre trial compared once-daily subcutaneous administration of vosoritide with placebo i

50 inical application is envisioned as a single subcutaneous administration, and the lead tafenoquine po

51 to induce longer lasting analgesia following subcutaneous administration.

52 on frequency by limiting dilution assay upon subcutaneous administration.

53 Importantly, both intravenous and subcutaneous administrations of the fusion protein lower

54 ived 1 year of treatment with a well-defined subcutaneous AIT form (Alutard SQ 510) were tested for I

55 world evidence confirms the good efficacy of subcutaneous AIT with HDM mite allergoid in the treatmen

56 in basophil sensitivity after three weeks of subcutaneous allergen immunotherapy predicted the clinic

57 Subcutaneous allograft tumors with overexpression or kno

58 served the most significant phenotype in the subcutaneous and brown adipose tissues of KO mice, with

59 ors and lead to a high rate of cures in both subcutaneous and intra-cranial tumor models.

60 Parenteral immunization, specifically subcutaneous and intramuscular, is the most common vacci

61 In such patients, the efficacy and safety of subcutaneous and intravenous evinacumab, a fully human m

62 of (225)Ac-L1 was determined in human PSMA+ subcutaneous and micrometastatic models.

63 d by recurrent and unpredictable episodes of subcutaneous and mucosal swelling that can be life threa

64 Subcutaneous and muscle oedema are very common loco-regi

65 Subcutaneous and oral administration of modified elafin

66 In syngeneic mouse tumor models, subcutaneous and oral MSA-2 regimens were well tolerated

67 8)F-TRX uptake was assessed in vivo among 10 subcutaneous and orthotopic human xenograft models.

68 nd-loss of function studies and confirmed in subcutaneous and orthotopic mouse lung cancer models.

69 nanoformulation with synergistic efficacy in subcutaneous and orthotopic PDAC mouse models.

70 ty of S. aureus to cause infection in both a subcutaneous and sepsis model of infection.

71 Recommendations for use of subcutaneous and sublingual tablet allergen immunotherap

72 and fibrosis were determined in biopsies of subcutaneous and visceral adipose tissue (SCAT and VAT,

73 utomated segmentation of adipose tissue into subcutaneous and visceral adipose tissue is required.

74 he importance of body composition, amount of subcutaneous and visceral fat, liver and heart ectopic f

75 pids between the major fat depots located in subcutaneous and visceral regions may shed new light on

76 reatment using TCMCB07 with intraperitoneal, subcutaneous, and oral administration increased food int

77 vity of EasyCIE-SSI decreased in clean, skin/subcutaneous, and outpatient procedures in the external

78 n of zoledronic acid and test group 3 with a subcutaneous application of alendronic acid.

79 sed payloads at a ~5-fold slower rate in the subcutaneous area.

80 T) microdialysis and an in-depth analysis of subcutaneous AT histology.

81 in sensitivity in people.METHODSWe evaluated subcutaneous AT oxygen partial pressure (pO2); liver and

82 RB-C(KLAKLAK)(2)-mediated PDT treatment of subcutaneous B16-F10-Luc2 tumors in C57 mice resulted in

83 les inhibited tumor growth (34 +/- 11%) in a subcutaneous B16F10 murine melanoma model despite minima

84 tudy in overweight/obese human participants, subcutaneous BFKB8488A injection caused transient body w

85 to immune responses observed after multiple subcutaneous bolus injections, and led to immune protect

86 atients received up to nine 6-week cycles of subcutaneous bortezomib (1.3 mg/m(2) of body surface are

87 ens of oral panobinostat in combination with subcutaneous bortezomib and oral dexamethasone for this

88 ce weekly, or 10 mg three times weekly, plus subcutaneous bortezomib and oral dexamethasone.

89 Subcutaneous bortezomib has replaced intravenous bortezo

90 Subcutaneous C2C administration reduced pain-like behavi

91 afforded complete protection in mice against subcutaneous challenge with 8 x 10(5) CFU (80,000 50% le

92 All patients received routine subcutaneous chemical venous thromboembolism prophylaxis

93 Subcutaneous CHL-GLP-1R xenografts were visualized using

94 n was determined in BALB/c nude mice bearing subcutaneous CHL-GLP-1R xenografts.

95 in vitro and in vivo, in models of lung and subcutaneous coinfection.

96 rst 7 days, followed by 5 mg twice daily) or subcutaneous dalteparin (at a dose of 200 IU per kilogra

97 Patients received subcutaneous daratumumab (DARA SC) weekly in cycles 1 to

98 Patients received 1800 mg of subcutaneous daratumumab co-formulated with 2000 U/mL re

99 data could contribute to the approval of the subcutaneous daratumumab formulation by regulatory bodie

100 rom a treatment-related adverse event in the subcutaneous daratumumab group (febrile neutropenia) and

101 Subcutaneous daratumumab is thought to be easier to admi

102 Subcutaneous daratumumab was non-inferior to intravenous

103 cross cohorts = 0.49) and that adipocytes in subcutaneous depots are larger than their visceral count

104 ion [95% CI, $76.3-$95.9 billion]), skin and subcutaneous diseases ($85.0 billion [95% CI, $80.5-$90.

105 atients with AMI were randomized to a single subcutaneous dose of selatogrel of 8 or 16 mg.

106 s in the acetic acid stretch assay (AASA) at subcutaneous doses of 1 mg/kg.

107 ts: driveline entry point (77% of patients), subcutaneous driveline path (87%), pump pocket (49%), an

108 t volumes-abdominal superficial (sSAT), deep subcutaneous (dSAT), and internal (IAT) adipose tissue-w

109 run-in, patients were randomized to commence subcutaneous dupilumab (600 mg loading dose, then 300 mg

110 A pilot electrographic study using subcutaneous electrodes reveals that dietary CAF does no

111 egy of avoiding pharmacoenhancers and adding subcutaneous enfuvirtide during post-transplant cyclopho

112 ly) or high regimen thromboprophylaxis (i.e. subcutaneous enoxaparin 4,000 international units bid or

113 the use of standard thromboprophylaxis (i.e. subcutaneous enoxaparin 4,000 international units once d

114 n = 109) or 1.8 mg/kg (n = 108); or 40 mg of subcutaneous enoxaparin once daily (n = 105) or 2.5 mg o

115 e randomly assigned to the following groups: subcutaneous evinacumab at a dose of 450 mg weekly (40 p

116 level between the groups assigned to receive subcutaneous evinacumab at a dose of 450 mg weekly, 300

117 e and on stable lipid-lowering therapy began subcutaneous evolocumab 420 mg monthly or 420 mg every 2

118 blind, multinational trial comparing monthly subcutaneous evolocumab 420 mg with placebo in PLHIV wit

119 am13a knockout (KO) have a lower visceral to subcutaneous fat (VAT/SAT) ratio after high-fat diet cha

120 ly with these variables (P < .001 except for subcutaneous fat area vs age [P = .003]).

121 ease, myocardial infarction and visceral and subcutaneous fat distribution; however, the underlying p

122 Primary ASCs isolated from rat and human subcutaneous fat exhibited mechanical memory, demonstrat

123 rt, and perirenal fat volume; fat content in subcutaneous fat in the hip region in both sexes; fatty

124 -ray absorptiometry, and organ fat including subcutaneous fat index, visceral fat index, pericardial

125 IV epidemic, lipodystrophy, characterized by subcutaneous fat loss (lipoatrophy), with or without cen

126 Visceral fat (omentum) and abdominal subcutaneous fat of 4 patients were also not infected wi

127 y was to characterize ASCs isolated from the subcutaneous fat of domestic pigs (pASCs) and examine th

128 animal skin, carcass surface, fresh meat and subcutaneous fat samples) at a commercial abattoir, usin

129 The results suggest that, using subcutaneous fat samples, a portable NIRS could be used

130 mes by using the spectra from fresh meat and subcutaneous fat samples.

131 vealed a strong negative correlation between subcutaneous fat stores and dominance rank in the inters

132 how that HSF1 levels are higher in brown and subcutaneous fat tissues than in those in the visceral d

133 Human subcutaneous fat was cultured in vitro to promote blood

134 NIRS measurements in the carcass surface and subcutaneous fat were able to correctly classify 75.9% a

135 rol level, high glucose level, and abdominal subcutaneous fat were included in the obtained model.

136 l cholesterol level, high glucose level, and subcutaneous fat.

137 in vivo Dox distribution and retention in a subcutaneous flank colorectal murine tumor, and therapeu

138 tics, efficacy, and safety of the fixed-dose subcutaneous formulation compared to intravenous pertuzu

139 ective in treating HS, was evaluated using a subcutaneous formulation in patients with HS naive to or

140 A subcutaneous formulation of pertuzumab and trastuzumab w

141 ogel copolymer, that instantaneously forms a subcutaneous gel-depot following injection.

142 ple with type 1 diabetes rely on an accurate subcutaneous glucose sensor and an infusion cannula that

143 y diagnosed overt type 1 diabetes to receive subcutaneous golimumab or placebo for 52 weeks.

144 more than 2% of patients (seven [3%] in the subcutaneous group and 11 [4%] in the intravenous group)

145 mum C(trough) was 593 mug/mL (SD 306) in the subcutaneous group and 522 mug/mL (226) in the intraveno

146 was seen in 108 (41%) of 263 patients in the subcutaneous group and 96 (37%) of 259 in the intravenou

147 Three patients in the subcutaneous group and one in the intravenous group did

148 om 522 were recruited and randomly assigned (subcutaneous group n=263; intravenous group n=259).

149 locks to receive daratumumab subcutaneously (subcutaneous group) or intravenously (intravenous group)

150 ine DMARD and previous TNF inhibitor use) to subcutaneous guselkumab 100 mg every 4 weeks; guselkumab

151 cacy studies were conducted on mouse bearing subcutaneous HCT-116 cancer.

152 A total of 849 patients (426 in the subcutaneous ICD group and 423 in the transvenous ICD gr

153 complications occurred in 31 patients in the subcutaneous ICD group and in 44 in the transvenous ICD

154 Death occurred in 83 patients in the subcutaneous ICD group and in 68 in the transvenous ICD

155 cation for pacing were assigned to receive a subcutaneous ICD or transvenous ICD.

156 5% confidence interval for the hazard ratio (subcutaneous ICD vs. transvenous ICD) was 1.45.

157 for an ICD but no indication for pacing, the subcutaneous ICD was noninferior to the transvenous ICD

158 TCF1(+)PD-1(+)CD8(+) T cells as compared to subcutaneous immunization (SNP-SC).

159 Subcutaneous immunization of mice with PM plus alum inhi

160 ss pollen allergy were randomized to receive subcutaneous immunotherapy (n = 18) or to an open contro

161 Widely accepted loading protocols for rush subcutaneous immunotherapy (rSCIT) have not been establi

162 ulatory (T(FR)) cells following grass pollen subcutaneous immunotherapy (SCIT) and sublingual immunot

163 ell responses prospectively during 24 months subcutaneous immunotherapy (SCIT) in 25 rhinitis, docume

164 Subcutaneous immunotherapy is recommended as an adjunct

165 Subcutaneous immunotherapy led to a 447-fold decrease in

166 Subcutaneous immunotherapy stimulates progressive integr

167 rgen immunotherapy (AIT) is to be preferred (subcutaneous immunotherapy, SCIT, vs sublingual immunoth

168 esign and testing of a long-acting reservoir subcutaneous implant capable of releasing cabotegravir f

169 The subcutaneous implantable cardioverter-defibrillator (ICD

170 lipopolysaccharide (LPS) as a pathogen, 2) a subcutaneous implantation model to determine the relatio

171 n these hPBMCs immune system RRGS animals by subcutaneous implantation of a human tumor cell line.

172 Subcutaneous implantation of the porous materials did no

173 sed on the route of infection, including (i) subcutaneous infection models, (ii) intradermal infectio

174 calized ulcerative lesion progression during subcutaneous infections in mice.

175 s, as well as in mouse models of LPS-induced subcutaneous inflammation.

176 ombination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg t

177 e either sildenafil 10 mg/kg/d or placebo by subcutaneous injection from GD24 to GD30.

178 crylate) were first characterized in a mouse subcutaneous injection model.

179 , respectively, 35%, 29% and 23% that of the subcutaneous injection of 1 U kg(-1) insulin.

180 Furthermore, subcutaneous injection of 5 ug of the probe in intact or

181 0.5-mL subcutaneous injection of 500 ug of adjuvanted (1 dose)

182 cell RNA sequencing, in vitro coculture, and subcutaneous injection of MSCs and myeloma cells into mi

183 multiple peptidic cargoes can be achieved by subcutaneous injection of the construct.

184 Participants were given a subcutaneous injection of their allocated treatment at d

185 lisiran (284 mg) or placebo, administered by subcutaneous injection on day 1, day 90, and every 6 mon

186 Immunization of mice by subcutaneous injection or epicutaneous laser microporati

187 ombination of pertuzumab and trastuzumab for subcutaneous injection provides non-inferior cycle 7 per

188 clearance and slow release kinetics from the subcutaneous injection site.

189 f 400 U per kilogram three times per week by subcutaneous injection through 32 completed weeks of pos

190 ation) within the fixed-dose combination for subcutaneous injection versus intravenous pertuzumab plu

191 ct via laser-generated skin micropores or by subcutaneous injection with or without alum.

192 0-29-a 2-nt longer version of nusinersen-via subcutaneous injection.

193 nt for an extended period following a single subcutaneous injection.

194 cokinetic and safety profiles than IP6 after subcutaneous injection.

195 til week 50 as 40 mg per 0.4 mL citrate free subcutaneous injection.

196 nificant limitations, including the need for subcutaneous injections and frequent monitoring.

197 0 mg bimekizumab, which were administered as subcutaneous injections every 4 weeks for 12 weeks.

198 -week treatment period administered by daily subcutaneous injections in their homes by trained caregi

199 NMDA receptors (NMDARs) during development [subcutaneous injections of 30 mg/kg ketamine (KET) on po

200 Rats received subcutaneous injections of CORT for 3 weeks and Reelin w

201 Subcutaneous injections of CsA-loaded DIANAs in mice pro

202 omly assigned to groups that received weekly subcutaneous injections of dupilumab (300 mg, n = 23) or

203 y assigned in a 2:1 ratio to receive monthly subcutaneous injections of evolocumab (420 mg) or placeb

204 They received seven subcutaneous injections of GD2/GD3 vaccine spanning 1 ye

205 use and C-reactive protein concentration) to subcutaneous injections of guselkumab 100 mg every 4 wee

206 ous familial hypercholesterolemia to receive subcutaneous injections of inclisiran sodium (at a dose

207 ong metabolic disease that requires frequent subcutaneous injections of insulin.

208 ecific small hairpin RNAs or that were given subcutaneous injections of siRNAs had reduced levels of

209 iven intraperitoneal injections of S100A8 or subcutaneous injections of Staphylococcus aureus.

210 Participants were randomly assigned (1:1) subcutaneous injections once a week of either dulaglutid

211 eive 25 mg clazakizumab or placebo (4-weekly subcutaneous injections) for 12 weeks (part A), followed

212 y been re-investigated as an alternative for subcutaneous injections.

213 Moreover, subcutaneous inoculation of RGS12-overexpressed OSCC cel

214 Moreover, in a mouse model of subcutaneous inoculation with P. aeruginosa, rTCP96 redu

215 scalimab (0.03, 0.1, 0.3, 1, or 3 mg/kg), or subcutaneous iscalimab (3 mg/kg), or placebo.

216 s later, the patient noticed a subcentimeter subcutaneous lump in his thigh.

217 acy of the drug in suppressing the growth of subcutaneous melanoma tumors and prolonging survival.

218 mTOR with rapamycin suppressed the growth of subcutaneous MET-mutant cell grafts in mice, including t

219 Furthermore, the subcutaneous metastatic disease remained stable during t

220 erformed on female athymic nude mice bearing subcutaneous MKN-45 xenografts.

221 ration in human tumors more closely than the subcutaneous models, alongside similar GD2 and MHC class

222 gly, in vivo nilotinib treatment in a Kcl-22 subcutaneous mouse model resulted in morphological chang

223 ISFIs were intratumorally injected into subcutaneous murine tumors then exposed to C-TUS (exposu

224 liver biopsies from 43 patients who received subcutaneous NGM282 (1 mg, n = 24; 3 mg, n = 19) once da

225 The impact of chronic, twice-daily, subcutaneous nicotine at two doses (0.3 and 0.5 mg/kg) v

226 nd splenic microenvironment of two syngeneic subcutaneous (NXS2 and 9464D), and a spontaneous transge

227 nd 30% of the patients showed post-treatment subcutaneous oedema (p = 0.002 to 0.03), muscle oedema (

228 with relapsing multiple sclerosis to receive subcutaneous ofatumumab (20 mg every 4 weeks after 20-mg

229 were exposed to nicotine (0.2 or 0.4 mg/kg, subcutaneous) once daily for 7 days.

230 11)C-PS13 was evaluated in ICRscid mice with subcutaneous or intraperitoneal human OVCAR-3 OvCa xenog

231 generally demonstrate poor growth as either subcutaneous or intraperitoneal xenografts.

232 Patients were randomly assigned to receive subcutaneous or intravenous evinacumab or placebo.

233 atening attacks characterized by swelling of subcutaneous or submucosal tissues.

234 s through ventricular catheters connected to subcutaneous osmotic pumps.

235 n this study, C57Bl/6 mice were treated with subcutaneous pellets containing vehicle, the AMPK activa

236 jection into RAIC during an inflammatory (by subcutaneous peripheral injection of formalin) nocicepti

237 erum free fatty acids (FFAs) and decrease in subcutaneous/peritoneal fat depots compared to non-tumor

238 /platelet-activating factor-induced vascular subcutaneous permeability.

239 were randomly assigned (1:2) to groups given subcutaneous placebo (n = 25) or aldafermin 1 mg (n = 53

240 Patients were randomised 1:1 to receive subcutaneous placebo or galcanezumab 120 mg per month (w

241 r transplantation into the kidney capsule or subcutaneous pockets of mice for up to 2 weeks.

242 nd then injected within a fibrin matrix into subcutaneous pockets on the dorsal flanks of SCID mice.

243 lopment as a single-dose therapeutic via the subcutaneous route with the potential for broader patien

244 pted as a viable "alternative" option to the subcutaneous route.

245 and pathological consequences of rectal and subcutaneous routes of ZIKV infection using a mouse mode

246 who were randomized to weekly treatment with subcutaneous RPC4046, 180 mg (n = 19), 360 mg (n = 26),

247 The subcutaneous (S) implantable cardioverter-defibrillator

248 by 0.39, 0.96 and 0.73 log(10) CFU following subcutaneous (s.c.) BCG, intranasal (i.n.) BCG, or BCG s

249 In contrast, subcutaneous (s.c.) immunization conferred no protection

250 Numerous small subcutaneous (s.c.) photophores (bioluminescent organs)

251 lasses and MRI-determined visceral (VAT) and subcutaneous (SAT) adipose tissue.

252 harmacokinetic study was conducted: a single subcutaneous (SC) dose of 20 or 40 mg/kg (Dose Groups 1

253 ) or double doses (48 h and 5 days post-TBI) subcutaneous (SC) injection increased 30-day survival of

254 Subcutaneous semaglutide and canagliflozin increased dia

255 Odds of stroke were lower with subcutaneous semaglutide and dulaglutide.

256 ulation of fat at visceral (VAT) compared to subcutaneous sites (SAT) has been suspected as a key det

257 E by PET/CT imaging in NOD-SCID mice bearing subcutaneous somatostatin receptor-expressing AR42J tumo

258 Blood and subcutaneous (SUBQ) adipose tissue were collected at bas

259 lesions, were allocated to either 8 weeks of subcutaneous teriparatide (20 ug/day) or placebo injecti

260 unction, superior compared to the effects of subcutaneous therapy.

261 n adipose tissue, higher in visceral than in subcutaneous tissue, increased in obesity, and further i

262 reducing the number of devices inserted into subcutaneous tissue.

263 , although lower ceramide concentrations, in subcutaneous tissue.

264 nked foam displays higher compatibility with subcutaneous tissues than the widely used biomaterial-po

265 ad to adipose tissue redistribution from the subcutaneous to abdominal area, and augments sympathetic

266 ric mean ratio of pertuzumab serum C(trough) subcutaneous to serum C(trough) intravenous was 1.22 (90

267 Subcutaneous transplantation into immunocompetent as wel

268 Indeed, subcutaneous transplantation of sensitive and resistant

269 VZV and HCMV mouse models were developed by subcutaneous transplantation of skin into SCID/beige or

270 k-old athymic female nude mice (induced with subcutaneous triple negative xenograft breast tumors) we

271 st HCT-116 cells and significantly inhibited subcutaneous tumor growth in mice compared with 5-FU.

272 ablished subcutaneously in nude mice and the subcutaneous tumor tissue was then orthotopically implan

273 in both healthy nude mice and nude mice with subcutaneous tumor to validate the contrast effects and

274 Pbrm1 deficient Renca subcutaneous tumors in mice are more resistance to ICB,

275 CDH11 reduced growth of pre-established mT3 subcutaneous tumors only if T and B cells were present i

276 Subcutaneous tumors were established from a triple-negat

277 with T-cell-loaded films and implanted into subcutaneous tumours in mice improved the duration of st

278 ame melanomas had similar capacities to form subcutaneous tumours, but MCT1(high) cells formed more m

279 n had little effect on the growth of primary subcutaneous tumours, but resulted in depletion of circu

280 enous injection than did melanoma cells from subcutaneous tumours.

281 attenuation), and fat (L1-level visceral-to-subcutaneous [V/S] ratio) measures were derived from non

282 Subcutaneous VRC01 as single or multiple doses is safe a

283 Subcutaneous VRC01 was safe and well tolerated with only

284 ke in BMAT is greater than in axial bones or subcutaneous WAT and can be greater than that in skeleta

285 e flux coupled with reduced fat cell size in subcutaneous WAT depots.

286 identifies at least two distinct classes of subcutaneous white adipocytes.

287 which stimulates beige adipose formation in subcutaneous white adipose tissue (SC WAT), would induce

288 ted with increased amounts of beige cells in subcutaneous white adipose tissue (sWAT) and increased t

289 Aifm2 in BAT and subcutaneous white adipose tissue (WAT) promotes oxygen

290 Inguinal subcutaneous white adipose tissue and dWAT in REDD1 knoc

291 es expressing UCP1 (uncoupling-protein-1) in subcutaneous white adipose tissue which, together with c

292 ant reductions of sympathetic innervation of subcutaneous white and brown adipose tissue.

293 protein 1 (UCP1)-independent respiration in subcutaneous white fat, 3) change the gut microbiota com

294 To date, there is a lack of evidence whether subcutaneous wound irrigation is beneficial in terms of

295 Intraoperative subcutaneous wound irrigation with antiseptic 0.04% poly

296 Subcutaneous xenograft tumors were grown in NSG mice fro

297 beled with (64)Cu or (89)Zr and evaluated in subcutaneous xenografts and adoptive cell transfer mouse

298 tors of oxidative stress, but developed into subcutaneous xenografts with growth comparable with that

299 r-targeted photodynamic therapy in mice with subcutaneous xenografts, we observed a substantial and i

300 sulted in significant protection from lethal subcutaneous ZIKV challenge, further eliciting robust me